SG11201907240XA - Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof - Google Patents

Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof

Info

Publication number
SG11201907240XA
SG11201907240XA SG11201907240XA SG11201907240XA SG11201907240XA SG 11201907240X A SG11201907240X A SG 11201907240XA SG 11201907240X A SG11201907240X A SG 11201907240XA SG 11201907240X A SG11201907240X A SG 11201907240XA SG 11201907240X A SG11201907240X A SG 11201907240XA
Authority
SG
Singapore
Prior art keywords
compound
activity
somatostatin receptor
agonistic activity
pharmaceutical use
Prior art date
Application number
SG11201907240XA
Other languages
English (en)
Inventor
Akiharu Ishida
Atsushi Yoshida
Hidenori Miyata
Tomoyuki Shono
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of SG11201907240XA publication Critical patent/SG11201907240XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201907240XA 2017-02-08 2018-02-07 Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof SG11201907240XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017021363 2017-02-08
PCT/JP2018/004111 WO2018147300A1 (ja) 2017-02-08 2018-02-07 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
SG11201907240XA true SG11201907240XA (en) 2019-09-27

Family

ID=63108324

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907240XA SG11201907240XA (en) 2017-02-08 2018-02-07 Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof

Country Status (15)

Country Link
US (1) US20200000816A1 (he)
EP (1) EP3581569A4 (he)
JP (1) JPWO2018147300A1 (he)
KR (1) KR20190114986A (he)
CN (1) CN110300749A (he)
AU (1) AU2018219644A1 (he)
BR (1) BR112019016433A2 (he)
CA (1) CA3053091A1 (he)
IL (1) IL268444A (he)
MX (1) MX2019009419A (he)
PH (1) PH12019501802A1 (he)
RU (1) RU2019124888A (he)
SG (1) SG11201907240XA (he)
TW (1) TW201835081A (he)
WO (1) WO2018147300A1 (he)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170284A1 (en) * 2017-03-16 2018-09-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2019157458A1 (en) 2018-02-12 2019-08-15 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TW202016101A (zh) * 2018-06-15 2020-05-01 日商小野藥品工業股份有限公司 哌啶醇衍生物的新穎鹽及新穎結晶形
EP3853218A4 (en) 2018-09-18 2022-02-16 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND USES THEREOF
CN109115914B (zh) * 2018-10-03 2021-06-04 四川中科微纳科技有限公司 一种分离盐酸雷莫司琼和其s型对映异构体的高效液相色谱方法
CN109115913B (zh) * 2018-10-03 2021-08-06 济南迪安医学检验中心有限公司 一种基于常规苯基色谱柱分离盐酸雷莫司琼和其s型对映异构体的hplc方法
JP7365094B2 (ja) * 2019-04-22 2023-10-19 株式会社Screenホールディングス 薬効評価方法、コンピュータプログラムおよび記録媒体
US11479540B2 (en) 2019-08-14 2022-10-25 Crinetics Pharmaceuticals, Inc. Nonpeptide somatostatin type 5 receptor agonists and uses thereof
CA3207378A1 (en) 2021-02-17 2022-08-25 Yuxin Zhao Crystalline forms of a somatostatin modulator
WO2024089668A1 (en) * 2022-10-28 2024-05-02 Basecamp Bio Inc. Somatostatin receptor 2 agonists and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
KR100388120B1 (ko) 1998-05-11 2003-06-18 다케다 야쿠힌 고교 가부시키가이샤 저혈당 및 저지질혈 활성을 갖는 옥시이미노알칸산 유도체
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMIN DERIVATIVES
EP1228067B1 (en) 1999-11-10 2004-07-14 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
DK1285651T3 (da) 2000-04-28 2010-12-13 Takeda Pharmaceutical Melanin-koncentrerende hormon-antagonister
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
WO2002091125A2 (en) 2001-05-07 2002-11-14 Ibiz Technology Corp. Protective case and keyboard system for a handheld computer
WO2003042204A1 (fr) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Derive d'amine
AU2002363655A1 (en) 2001-11-14 2003-05-26 Novartis Ag Non-peptide somatostatin receptor ligands
KR100961332B1 (ko) 2001-11-28 2010-06-04 입센 파마 에스.에이.에스 5-술파닐-4h-1,2,4-트리아졸 유도체 및 의약으로서 그의용도
CA2506735A1 (en) 2002-11-19 2004-06-03 Hidenori Abe Indole derivatives as somatostatin agonists or antagonists
EP1734040A4 (en) * 2004-03-23 2007-11-28 Banyu Pharma Co Ltd SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
WO2006007448A2 (en) 2004-06-17 2006-01-19 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
AU2007309708A1 (en) 2006-03-13 2008-05-02 Merck Sharp & Dohme Corp. Somatostatin agonists
JP2009155283A (ja) 2007-12-27 2009-07-16 Sumitomo Chemical Co Ltd オキサゾリジン化合物、オキサゾリドン化合物およびその中間体の製造方法
JP6299591B2 (ja) 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
AU2014325078B2 (en) * 2013-09-30 2018-10-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity to somatostatin receptor and medicinal use thereof
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2017003724A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof

Also Published As

Publication number Publication date
TW201835081A (zh) 2018-10-01
CN110300749A (zh) 2019-10-01
EP3581569A4 (en) 2020-02-19
WO2018147300A1 (ja) 2018-08-16
EP3581569A1 (en) 2019-12-18
BR112019016433A2 (pt) 2020-04-07
KR20190114986A (ko) 2019-10-10
MX2019009419A (es) 2019-10-02
PH12019501802A1 (en) 2020-03-02
JPWO2018147300A1 (ja) 2019-11-21
US20200000816A1 (en) 2020-01-02
IL268444A (he) 2019-09-26
RU2019124888A (ru) 2021-03-10
CA3053091A1 (en) 2018-08-16
AU2018219644A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
SG11201907240XA (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
PH12015502524B1 (en) New somatostatin receptor subtype 4 (sstr4) agonists
MX2023007192A (es) Inhibidores de prmt5.
MX2016003582A (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
PH12020550265A1 (en) Benzimidazole derivatives and their uses
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
JO3442B1 (ar) مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
MX2021010700A (es) Compuestos utiles en la terapia del vih.
NZ738990A (en) Cgrp receptor antagonists
MX2021015188A (es) Moduladores de nueva generacion del estimulador de genes de interferon (sting).
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.